Skip to content

Effects of Periodontal Therapy on Markers of Acute Phase Response, Oxidative Stress

Effects of Periodontal Therapy on Markers of Acute Phase Response (APR), Oxidative Stress: Phase II {Formerly UNC Biomedical IRB Study # DENT-2019}

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03375372
Acronym
BCU2
Enrollment
106
Registered
2017-12-18
Start date
2003-04-11
Completion date
2005-06-04
Last updated
2017-12-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Periodontitis

Brief summary

This study began enrollment in 2003 with final report completed in October of 2015. This submission is being provided to acquire an NCT number. This study was successfully executed according to protocol with full enrollment and completion of 89.7% of subjects. Subjects were enrolled into a two arm study 1) Combined therapy (scaling and root planing plus Crest products) vs. 2) delayed treatment. Subjects were followed for 6 months and a wide and extensive battery of biological samples were collected to determine the effects of treatment on the local and systemic inflammatory response.

Detailed description

The design for this study was a single-blinded, delayed treatment, controlled, randomized, clinical trial. A total of 106 subjects, 2 sets of 53 patients each in one of 2 arms, were enrolled. For both groups at 6 weeks, 3 months, and 6 months periodontal measures, gingival crevicular fluid, and plaque were taken using standardized techniques. Blood for serum was collected at each time point, plus at an additional 2 week visit. GCF samples were collected and analyzed for PGE2 and IL-1 to provide a mediator assessment of periodontal status.These GCF data and the clinical changes were used to assure that the therapy provided had resulted in a local therapeutic benefit. These data were primarily useful as it relates to changes in systemic levels of mediators. Subjects were recruited from the surrounding communities by means of flyer advertisements, as well as media advertisements in weekly newspapers and on the radio. Recruitment focused on subjects between the ages of 18 and 64 years with periodontal disease. The investigators excluded persons who have less than 20 teeth; who had any serious systemic disease including: auto-immune type disorders (i.e. systemic lupus erythematous), immunosuppression (chronic systemic c steroid use, cancer chemotherapy or HIV infection), chronic liver disease including hepatitis, or diabetes mellitus; extremely obese (BMI \<40), are pregnant, or who abuse alcohol or drugs. Subjects were selected from periodontal screening examinations as having 4 or more sites with pocket depths of 5 or more mm and two or more sites with attachment loss of 3 mm or more and who required scaling and root planing. The Phase II set of 106 patients had periodontal therapy consisting of one of two treatments: Treatment 1: A 6-week observation period (treatment delay), then full-mouth scaling and root planing plus specific oral hygiene regimen (OHR) (Group 1); Treatment 2: A 6-week observation period (treatment delay), then a further 6-month observation period (delayed treatment), followed by scaling and root planing plus specific oral hygiene regimen (OHR) at 6 months (Group 2).

Interventions

PROCEDUREScaling and Root Planing (S&RP)

dental Scaling and Root Planing and oral hygiene regimen

Sponsors

University of North Carolina, Chapel Hill
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 64 Years
Healthy volunteers
Yes

Inclusion criteria

* subjects with four or more periodontal pockets of five millimeters or greater and two or more sites with an clinical attachment loss of three millimeters or greater.

Exclusion criteria

* subjects with less than 20 teeth * subjects with serious systemic diseases (lupus, systemic erythematous), immunosuppression (chronic systemic steroid use, cancer, chemotherapy, or HIV infection), chronic liver disease including hepatitis or diabetes mellitus. * Body Mass Index of of 40 or greater * pregnant * abuse alcohol or drugs

Design outcomes

Primary

MeasureTime frameDescription
Effects of S&RP & OHR on Apolipoprotein A6 months post S&RPDelta log value mg/dL 6 months post S&RP & OHR
Effects of S&RP & OHR on sCD-146 months post S&RPDelta log value µg/ml 6 months post S&RP & OHR
Effects of S&RP & OHR on C-Reactive protein6 months post S&RPDelta log value pg/ml 6 months post S&RP & OHR
Effects of S&RP & OHR on HDL cholesterol6 months post S&RPDelta log value mg/dL 6 months post S&RP & OHR
Effects of S&RP & OHR on LDL cholesterol6 months post S&RPDelta log value mg/dL 6 months post S&RP & OHR
Effects of S&RP & OHR on VLDL cholesterol6 months post S&RPDelta log value mg/dL post S&RP & OHR
Effects of S&RP & OHR on Triglycerides6 months post S&RPDelta log value mg/dL 6 months post S&RP & OHR
Effects of S&RP & OHR on Homocysteine6 months post S&RPDelta log value μmol/L 6 months post S&RP & OHR
Effects of S&RP & OHR on 8-isoprostane6 months post S&RPDelta log value pg/ml 6 months post S&RP & OHR
Effects of S&RP & OHR on sICAM6 months post S&RPDelta log value pg/ml 6 months post S&RP & OHR

Secondary

MeasureTime frameDescription
Relationship between S&RP and OHR on PGE2 & IL-1beta6 months post S&RPto determine the relationship between the effects of S&RP plus OHR on levels of systemic inflammation and local changes in periodontal status, GCF levels of PGE2 and IL-1 and the periodontal microbiota, quantifying the levels of 40 organisms.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026